BMC Cardiovascular Disorders, 2017 Background Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS).
Pravesh Kumar Bundhun +2 more
doaj +1 more source
Recurrent thrombosis rescued by fondaparinux in high‐risk patients: A case series
Research and Practice in Thrombosis and Haemostasis, 2022 Background Recurrent thrombosis treatment options are limited when anticoagulation with dose escalation of low molecular weight heparin or unfractionated heparin fail. Fondaparinux is a pure, synthetic pentasaccharide that consists of heparin's essential
Mégane Tanguay, Chantal Séguin
doaj +1 more source
Diagnóstico y tratamiento de la trombosis venosa profunda [PDF]
, 2007 Deep-vein thrombosis (DVT) is a common condition that can lead to complications such as postphlebitic syndrome, pulmonary embolism and death. Currently, an algorithm strategy combining pretest probability, D-dimer testing and compression ultrasonography ...
Garcia, R. (R.) +4 more
core
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]
, 2019 © The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A +5 more
core +2 more sources
Quantifying Patient Reported and Documented Compliance with Adjuncts to Venous Thromboembolism Prophylaxis [PDF]
, 2017 Objectives: 1. Measure patient compliance with pharmacologic, mechanical and ambulatory prophylactic measures. 2. Evaluate for agreement between nursing documentation and patient reported compliance with mechanical and ambulatory prophylactic measures ...
Bauer, MD, Tyler M. +7 more
core +1 more source
FONDAPARINUX IN THE TREATMENT OF ACUTE CORONARY SYNDROME
Атеротромбоз, 2017 Fondaparinux is a parenteral selective factor-Xa inhibitor. The drug is successfully used in the treatment of acute coronary syndrome, and is characterized by the ideal profile of effectiveness and safety. In the case of ACS without ST-segment elevation,
O. O. Shakhmatova
doaj +1 more source
Estudio comparativo entre el Fondaparinux y la Nadroparina en la prevención del tromboembolismo venoso tras artroplastias de rodillas [PDF]
, 2005 El fondaparinux pertenece a una nueva clase de agentes antitrombóticos, los inhibidores selectivos del factor Xa. Nuestro estudio se propone analizar las diferencias entre las complicaciones originadas por la utilización de fondaparinux sódico y una ...
Gava, R., Hernández Vaquero, Daniel
core
Preventing postsurgical venous thromboembolism: pharmacological approaches [PDF]
, 2011 The use of antithrombotic drugs for the prevention of venous thromboembolism (VTE) in patients undergoing surgery is presently based on solid principles and high-level scientific evidence.
Cerbone AM +4 more
core +1 more source
The Development of Assays for Heparanase Enzymatic Activity: Towards a Gold Standard
Molecules, 2018 The enzyme heparanase, an endo-β-glucuronidase, degrades heparan sulfate (HS) chains on the cell surface and in the extracellular matrix. Heparanase regulates numerous biological processes that drive tumour growth, metastasis and angiogenesis.
Mohit Chhabra, Vito Ferro
doaj +1 more source
Investigação recente em antitrombóticos. Novidades para o tratamento dos doentes com síndromas coronárias agudas [PDF]
, 2010 A terapêutica antitrombótica ocupa um lugar central no tratamento da doença coronária aguda. A sua importância foi reforçada com a generalização dos procedimentos de intervenção percutânea, em especial quando são implantados dispositivos intra-coronários.
Morais, João
core